Functionally, treatment with propionate (an agonist of FFAR2) significantly inhibited human lung cancer migration, invasion, and colony formation induced by TLR2 or TLR3 by attenuating the cAMP-AMPK-TAK1 signaling axis for the activation of NF-κB. The gene discussed is NFKB1; the disease is lung carcinoma.